Where regulators
stand, today.
One table for the compounds we track: FDA status, the 2026 compounding review and sport. Dated, sourced, updated when it moves.
Last reviewed 18 Nov 2026 by 6AM Research.
Compound by compound
Plain status, no prediction. Where we are not certain, we say check the current source.
| Compound | FDA approval | 503A compounding (2026) | WADA |
|---|---|---|---|
| BPC-157 | Not approved | PCAC recommended (Jul); covered by HHS interim policy (Oct) under 10 conditions; rulemaking pending | Prohibited (S0, named) |
| TB-500 | Not approved | PCAC recommended (Jul); covered by HHS interim policy (Oct); rulemaking pending | Prohibited (S2) |
| MOTS-c | Not approved | PCAC recommended (Jul); covered by HHS interim policy (Oct); rulemaking pending | Prohibited (S4.4.1, named) |
| Epitalon | Not approved | PCAC recommended (Jul); covered by HHS interim policy (Oct); rulemaking pending | Not named (2026 and 2027 Lists); check with your anti-doping body |
| Semax | Not approved | PCAC recommended (Jul); covered by HHS interim policy (Oct); rulemaking pending | Check with your anti-doping body |
| Selank | Not approved | Formerly Category 2; nomination withdrawn (FDA list, current 22 Apr 2026); not in July review; not covered by HHS policy | Not named (2026 and 2027 Lists); check with your anti-doping body |
| GHK-Cu | Not approved | Non-injectable routes in Category 1, under evaluation (re-added May); injectable nomination withdrawn from Category 2 (Apr); not in July review; committee discussion due by end of Feb 2027 | Not named (2026 and 2027 Lists); check with your anti-doping body |
| DSIP (emideltide) | Not approved | Formerly Category 2; nomination withdrawn (FDA list, current 22 Apr 2026); PCAC voted against listing (Jul, press-reported); not covered by HHS policy | Not named (2026 and 2027 Lists); check with your anti-doping body |
| Tesamorelin | Active ingredient of Egrifta, a prescription medicine approved in 2010 for one condition in adults with HIV; products sold online as “tesamorelin” are not that medicine | Not in July review; not covered by HHS policy | Prohibited (S2, named) |
| PT-141 (bremelanotide) | Active ingredient of Vyleesi, a prescription medicine approved in 2019 for one diagnosed condition in premenopausal women; products sold online as “PT-141” are not that medicine | Not in July review; not covered by HHS policy | Not named (2026 and 2027 Lists); check with your anti-doping body |
| KPV | Not approved | PCAC recommended (Jul); covered by HHS interim policy (Oct); rulemaking pending | Not named (2026 and 2027 Lists); check with your anti-doping body |
How we got here
- 2023Category 2 listings
FDA placed many popular peptides in Category 2 of its interim 503A bulks list, blocking compounding.
- Apr 202612 peptides leave Category 2
Nominations were withdrawn; removal did not make them eligible for compounding.
- 23–24 Jul 2026PCAC votes
The advisory committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A bulks list; by press reports, it voted against DSIP. FDA staff had recommended against all seven.
- 28–30 Oct 2026HHS interim policy
HHS said it will not act against licensed 503A compounders making the six recommended peptides, under ten conditions, while FDA rulemaking proceeds. Not approval; non-binding.
- NowRulemaking pending
Only FDA notice-and-comment rulemaking can put a peptide on the 503A bulks list. Research-use supply is a separate lane.
Approval is not compounding
A compounding listing lets licensed pharmacies prepare a substance on prescription. It is not FDA approval and makes no safety or efficacy finding.
Research use is a separate lane
None of this changes what research-use-only means.
Sport is stricter
WADA prohibits several of these at all times, whatever their regulatory status.
Sources
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; read 18 Nov 2026. www.fda.gov/media/94155/download
- Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List. April 2026. www.frierlevitt.com/articles/fda-peptides-do-not-compound-l…
- National Law Review. FDA Committee Supports Peptide Compounding: What Comes Next. 29 July 2026. natlawreview.com/article/fda-committee-supports-peptide-com…
- AJMC. FDA Panel Backs 6 Peptides for Compounding. 31 July 2026. ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee, July 23–24, 2026. Advisory committee calendar. www.fda.gov/advisory-committees/advisory-committee-calendar
- World Anti-Doping Agency. The Prohibited List. Current list. www.wada-ama.org/en/prohibited-list
- Federal Register (public inspection). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 2026-22192. Filed 28 October 2026. public-inspection.federalregister.gov/2026-22192.pdf
- Foley & Lardner. Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides. 30 October 2026. www.foley.com/?p=130749
Questions
How often is this updated?
Whenever FDA, the advisory committee or WADA publishes a change, and at least monthly. The date above is the last review.
Does a PCAC recommendation mean a peptide is legal?
No. It is advisory. Compounding stays off-limits until FDA finishes rulemaking, and research-use supply follows different rules again, which vary by country.
What did the October 2026 HHS policy change?
Licensed US compounders may prepare six peptides under ten conditions while FDA rulemaking proceeds. It is not approval. Our HHS policy explainer covers the detail.
Status changes. We date everything.
Get the 6:00 brief: one email a month when the rules move.
Request accessNo hype. Unsubscribe any time.